Kentucky-based Demeetra AgBio, Inc., a genetic engineering company, has announced its proprietary gene-editing platform, Cas-CLOVER, could be used to produce less harmful tobacco products, as well as therapeutic cannabinoids. For its part, Demeetra AgBio notes its platform, which is similar to the gene-editing technology CRISPR/Cas9, can be deployed in the tobacco and cannabis industries to create less harmful products. The U.S Food and Drug Administration (FDA) has Big Tobacco in its crosshairs and one biotech company reports it can help reform the industry. The technology is currently licensed to Demeetra AgBio and sister companies Hera BioLabs and Poseida Therapeutics, Deemetra AgBio CEO Jack Crawford recently told CRISPR Medicine News. Corteva Agriscience and the Broad Institute of MIT and Harvard hold the rights to the technology.
The U.S Food and Drug Administration (FDA) has Big Tobacco in its crosshairs and one biotech company reports it can help reform the industry.
Kentucky-based Demeetra AgBio, Inc., a genetic engineering company, has announced its proprietary gene-editing platform, Cas-CLOVER, could be used to produce less harmful tobacco products, as well as therapeutic cannabinoids.
Israeli...Read the full article @ The Growth Op